United States. Securities and Exchange Commission
Neurocrine Biosciences Inc., a leading biopharmaceutical company, recently filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on February 6, 2023. This filing reported a series of material events and corporate changes of importance to investors and security holders. As a current report, the Form 8-K
United States. Securities and Exchange Commission
According to a recent SEC filing, Fate Therapeutics Inc., a biopharmaceutical company, has submitted a report to the U.S. Securities and Exchange Commission on January 11, 2023. The company, which specializes in biological products, has reported one document filed with the form. This filing is a requirement for publicly-traded
United States. Securities and Exchange Commission
U.S.-based publicly traded company Gamida Cell Ltd. has filed a new form with the Securities and Exchange Commission (SEC). According to the SEC filing, Gamida Cell Ltd. has submitted their Form S-3 on January 11, 2023, providing investors with critical information about the company's financials and
United States. Securities and Exchange Commission
Bluebird Bio, Inc. has recently submitted a U.S. Securities and Exchange Commission (SEC) filing, specifically a Form 8-K, which is a "current report" used to document material events or corporate changes important to investors or security holders. The filing was made on December 29, 2022, and contains
United States. Securities and Exchange Commission
Moderna, Inc., a biotechnology company focused on the development of mRNA therapeutics, has filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on December 30, 2022. The SEC filing provides information on the company's director, officer, or owner of more than ten percent of
United States. Securities and Exchange Commission
According to a recent U.S. Securities and Exchange Commission filing, Amgen Inc. disclosed information regarding the company's director, officer, or owner of more than 10% of a class of equity securities registered under Section 12 of the '34 Act. The filing, made on November 10, 2022,
United States. Securities and Exchange Commission
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, has announced that its partner Genentech has launched a Phase 2a clinical study of OpRegen (RG6501), a retinal pigment epithelial cell therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to evaluate the safety
United States. Securities and Exchange Commission
Amgen Inc., a leading biopharmaceutical company, recently submitted a U.S. Securities and Exchange Commission (SEC) filing (Form 8-K) on November 3, 2022, reporting material events and corporate changes. This filing, which includes 16 documents, is available for public review on the SEC's website. As a biotech leader,
United States. Securities and Exchange Commission
Moderna, Inc., a biotechnology company, has filed a document with the U.S. Securities and Exchange Commission (SEC) detailing its equity securities and beneficial ownership. The filing, made on November 4, 2022, provides insight into the company's ownership structure and transactions involving its directors, officers, and major shareholders.
United States. Securities and Exchange Commission
Amgen Inc., a leading biopharmaceutical company, has filed a U.S. Securities and Exchange Commission (SEC) form 424B2, a prospectus form required for primary offerings of securities, on August 16, 2022. The filing includes information on the security being offered, including the price and method of distribution. As a publicly-traded
United States. Securities and Exchange Commission
Biotech giant Amgen Inc. filed a critical disclosure on August 12, 2022, with the Securities and Exchange Commission (SEC) under Form 4. The filing reveals key information about the company's executive officers and stock ownership. As a leading biopharmaceutical company, Amgen's disclosure is closely watched by
United States. Securities and Exchange Commission
Amgen Inc., a leading biopharmaceutical company, recently submitted a Form 8-K SEC filing to report material corporate changes. The filing, made on August 4, 2022, indicates that the company has experienced significant events or corporate changes that are of importance to investors or security holders. As a publicly-traded company, Amgen
